1 |
Vallée A, Safar ME, Blacher J. Essential hypertension: Definitions, hemodynamic, clinical and therapeutic review[J]. Presse Med, 2019, 48(1 Pt 1): 19. |
2 |
Arif M, Sadayappan S, Becker RC, et al. Epigenetic modification: a regulatory mechanism in essential hypertension[J]. Hypertens Res, 2019, 42(8): 1099. |
3 |
Guarner-Lans V, Ramírez-Higuera A, Rubio-Ruiz ME, et al. Early programming of adult systemic essential hypertension[J]. Int J Mol Sci, 2020, 21(4): 1203. |
4 |
Manosroi W, Williams GH. Genetics of human primary hypertension: focus on hormonal mechanisms[J]. Endocr Rev, 2019, 40(3): 825. |
5 |
Rahman F, Muthaiah N, Kumaramanickavel G. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension[J]. Indian J Pharmacol, 2021, 53(4): 301. |
6 |
Chen H, Shen FE, Tan XD, et al. Efficacy and safety of acupuncture for essential hypertension: a meta-analysis[J]. Med Sci Monit, 2018, 24: 2946. |
7 |
Franks PW. Identifying genes for primary hypertension: methodological limitations and gene-environment interactions[J]. J Hum Hypertens, 2009, 23(4): 227. |
8 |
Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology[J]. Trends Pharmacol Sci, 2002, 23(4): 177. |
9 |
Soubrier F, Cambien F. The angiotensin Ⅰ-converting enzyme gene polymorphism: implication in hypertension and myocardial infarction[J]. Curr Opin Nephrol Hypertens, 1994, 3(1): 25. |
10 |
Wang N, Li X, Zhang Q, et al. Association of angiotensin-converting enzyme gene polymorphism with pulse pressure and its interaction with obesity status in Heilongjiang province[J]. Clin Exp Hypertens, 2019, 41(1): 70. |
11 |
Chinese Guidelines for the Prevention and Treatment of Hypertension. Guidelines for the prevention and treatment of hypertension in China[J]. Cardiovasc J, 2018, 19: 1. |
12 |
Zhang WS, Jiang CQ, Cheng KK, et al. Alcohol sensitivity, alcohol use and hypertension in an older Chinese population: the Guangzhou Biobank Cohort Study[J]. Hypertens Res, 2009, 32(9): 741. |
13 |
Chiva-Blanch G, Badimon L. Benefits and risks of moderate alcohol consumption on cardiovascular disease: current findings and controversies[J]. Nutrients, 2019, 12(1): 108. |
14 |
Garfinkle MA. Salt and essential hypertension: pathophysiology and implications for treatment[J]. J Am Soc Hypertens, 2017, 11(6): 385. |
15 |
Joachimdass RJ, Subramaniam K, Sit NW, et al. Self-management using crude herbs and the health-related quality of life among adult patients with hypertension living in a suburban setting of Malaysia[J]. PLoS One, 2021, 16(9): e0257336. |
16 |
Wu L, He Y, Jiang B, et al. Association between serum uric acid level and hypertension in a Chinese elderly rural population[J]. Clin Exp Hypertens, 2017, 39(6): 505. |
17 |
Moslemi M, Mahdavi-Roshan M, Joukar F, et al. Food behaviors and its association with hypertension and cardiovascular diseases in Sowme'eh Sara (North of Iran): the PERSIAN Guilan Cohort Study (PGCS)[J]. Prev Nutr Food Sci, 2021, 26(3): 262. |
18 |
Li AL, Peng Q, Shao YQ, et al. The interaction on hypertension between family history and diabetes and other risk factors[J]. Sci Rep, 2021, 11(1): 4716. |
19 |
Westerdahl C, Li X, Sundquist J, et al. Family history as a predictor of hospitalization for hypertension in Sweden[J]. J Hypertens, 2013, 31(10): 1952. |
20 |
Jani Y, Kamberi A, Ferati F, et al. Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia[J]. Am J Cardiovasc Dis, 2014, 4(2): 58. |
21 |
Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension[J]. Obesity (Silver Spring), 2013, 21(1): 8. |
22 |
Smith PM, Hindmarch CC, Murphy D, et al. AT1 receptor blockade alters nutritional and biometric development in obesity-resistant and obesity-prone rats submitted to a high fat diet[J]. Front Psychol, 2014, 5: 832. |
23 |
Gates P. Arteriosclerosis with superimposed atherosclerosis is the cause not the consequence of essential hypertension[J]. Med Hypotheses, 2020, 144: 110236. |
24 |
Barrios V, Escobar C, Calderón A. Clinical profile and management of patients with hypertension and chronic ischemic heart disease according to BMI[J]. Obesity (Silver Spring), 2010, 18(10): 2017. |
25 |
Xu Y, Liu J, Wang J, et al. Establishment and verification of a nomogram prediction model of hypertension risk in Xinjiang Kazakhs[J]. Medicine (Baltimore), 2021, 100(42): e27600. |
26 |
Zhang Y, Maitikuerban B, Chen Y, et al. Correlation between classical transient receptor potential channel 1 gene polymorphism and microalbuminuria in patients with primary hypertension[J]. Clin Exp Hypertens, 2021, 43(5): 443. |
27 |
Dalai N, Cui H, Yan M, et al. Risk factors for the development of essential hypertension in a Mongolian population of China: a case-control study[J]. Genet Mol Res, 2014, 13(2): 3283. |
28 |
Sun F, He N, Zhang K, et al. Association of ACE gene A2350G and Ⅰ/D polymorphisms with essential hypertension in the northernmost province of China[J]. Clin Exp Hypertens, 2018, 40(1): 32. |
29 |
He Q, Fan C, Yu M, et al. Correction: associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population[J]. PLoS One, 2016, 11(5): e0156564. |
30 |
Zhang X, Wang Y, Zheng Y, et al. Effect of ACE, ACE2 and CYP11B2 gene polymorphisms and noise on essential hypertension among steelworkers in China: a case-control study[J]. BMC Med Genomics, 2022, 15(1): 22. |